neoantigen reactive tumor infiltrating lymphocytes

Neoantigen reactive tumor infiltrating lymphocytes (TILs) are a form of adoptive cell therapy in which a patient’s own immune cells, specifically T cells that have infiltrated the tumor and are capable of recognizing cancer-specific neoantigens, are isolated from the tumor tissue. These cells are then expanded ex vivo—often using stimulation with identified neoantigens—and reinfused into the patient to enhance anti-tumor immunity. The process involves identifying unique tumor-specific mutations (neoantigens), stimulating and enriching for TILs that react to these antigens, and expanding them for therapeutic use. This approach has shown promise in treating metastatic solid tumors such as melanoma, colorectal cancer, and gastric cancer by broadening the repertoire of both CD4+ and CD8+ neoantigen-reactive clones with improved memory phenotypes[1][2][3].

Other names

neoantigen-reactive TILneoantigen-specific TILneoantigen-enriched TIL